China Pharma Holdings (CPHI) Return on Capital Employed (2011 - 2026)
China Pharma Holdings (CPHI) posted Return on Capital Employed of 11.68% for Q1 2026, up 42.3% on a QoQ basis from 20.24% in Q4 2025, and up 3531.0% year-over-year from 0.32% in Q1 2025.
China Pharma Holdings (CPHI) Return on Capital Employed (2011 - 2026) Analysis & Trends
China Pharma Holdings' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 11.68% for Q1 2026.
- Quarterly Return on Capital Employed rose 3531.0% year-over-year to 11.68% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.68% (up 3531.0% YoY) and the FY2025 annual result came in at 20.84%, up 2220.0% from the prior year.
- Return on Capital Employed was 11.68% for Q1 2026 at China Pharma Holdings, up from 20.24% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 11.68% in Q1 2026 and bottomed at 83.42% in Q4 2022.
- A 5-year average of 41.12% and a median of 40.0% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed tumbled 5453 bps — and 2023, when it surged 5315 bps.
- China Pharma Holdings' Return on Capital Employed stood at 83.42% in 2022, then jumped by 64 bps to 30.27% in 2023, then plunged by 65 bps to 50.1% in 2024, then soared by 60 bps to 20.24% in 2025, then surged by 42 bps to 11.68% in 2026.
- Business Quant data shows CPHI's Return on Capital Employed at 11.68% in Q1 2026, 20.24% in Q4 2025, and 39.63% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | -11.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.68% |
| Dec 31, 2025 | -20.24% |
| Sep 30, 2025 | -39.63% |
| Jun 30, 2025 | -42.24% |
| Mar 31, 2025 | -46.99% |
| Dec 31, 2024 | -50.10% |
| Sep 30, 2024 | -50.28% |
| Jun 30, 2024 | -40.00% |
| Mar 31, 2024 | -30.85% |
| Dec 31, 2023 | -30.27% |
| Sep 30, 2023 | -32.30% |
| Jun 30, 2023 | -45.32% |
| Mar 31, 2023 | -53.73% |
| Dec 31, 2022 | -83.42% |
| Sep 30, 2022 | -68.32% |
| Jun 30, 2022 | -27.90% |
| Mar 31, 2022 | -25.75% |
| Dec 31, 2021 | -28.88% |
| Sep 30, 2021 | -38.48% |
| Jun 30, 2021 | -45.49% |